1.
Clin Case Rep
; 5(8): 1258-1260, 2017 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28781837
RESUMO
The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments.
2.
Am J Hematol
; 91(6): E305-7, 2016 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26950187